JP2013542228A - Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用 - Google Patents

Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用 Download PDF

Info

Publication number
JP2013542228A
JP2013542228A JP2013537156A JP2013537156A JP2013542228A JP 2013542228 A JP2013542228 A JP 2013542228A JP 2013537156 A JP2013537156 A JP 2013537156A JP 2013537156 A JP2013537156 A JP 2013537156A JP 2013542228 A JP2013542228 A JP 2013542228A
Authority
JP
Japan
Prior art keywords
cancer
egfr
compound
treatment
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013537156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542228A5 (enExample
Inventor
マリア ブラッハマン，サスキア
フリッチュ，クリスティン
マイラ，ソーブール−マイケル
レネ スネル，クリスチャン
ガルシア−エチェベリア，カルロス
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013542228A publication Critical patent/JP2013542228A/ja
Publication of JP2013542228A5 publication Critical patent/JP2013542228A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013537156A 2010-11-08 2011-11-07 Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用 Pending JP2013542228A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41111710P 2010-11-08 2010-11-08
US61/411,117 2010-11-08
PCT/EP2011/069522 WO2012062694A1 (en) 2010-11-08 2011-11-07 Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016134705A Division JP2016222686A (ja) 2010-11-08 2016-07-07 Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用

Publications (2)

Publication Number Publication Date
JP2013542228A true JP2013542228A (ja) 2013-11-21
JP2013542228A5 JP2013542228A5 (enExample) 2014-12-25

Family

ID=44947083

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013537156A Pending JP2013542228A (ja) 2010-11-08 2011-11-07 Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
JP2016134705A Withdrawn JP2016222686A (ja) 2010-11-08 2016-07-07 Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
JP2018199647A Withdrawn JP2019048822A (ja) 2010-11-08 2018-10-24 Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
JP2020056250A Pending JP2020114849A (ja) 2010-11-08 2020-03-26 Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016134705A Withdrawn JP2016222686A (ja) 2010-11-08 2016-07-07 Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
JP2018199647A Withdrawn JP2019048822A (ja) 2010-11-08 2018-10-24 Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
JP2020056250A Pending JP2020114849A (ja) 2010-11-08 2020-03-26 Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用

Country Status (12)

Country Link
US (4) US20130209461A1 (enExample)
EP (1) EP2637661B1 (enExample)
JP (4) JP2013542228A (enExample)
KR (1) KR101854484B1 (enExample)
CN (2) CN103200943A (enExample)
AU (1) AU2011328227B2 (enExample)
BR (1) BR112013009624A2 (enExample)
CA (1) CA2815492C (enExample)
MX (1) MX360157B (enExample)
RU (1) RU2589695C2 (enExample)
TR (1) TR201802943T4 (enExample)
WO (1) WO2012062694A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539149A (ja) * 2013-12-06 2016-12-15 ノバルティス アーゲー アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017119219A (ru) * 2011-10-14 2018-11-02 Новартис Аг 2-карбоксамид циклоамино производные мочевины в комбинации с ингибиторами hsp90 для лечения пролиферативных заболеваний
MX2014005414A (es) * 2011-11-02 2014-09-22 Novartis Ag Derivados de 2-carboxamida-cicloamino-urea para su uso en el tratamiento de las enfermedades dependientes del factor de crecimiento endotelial vascular (vegf).
IN2015DN00450A (enExample) * 2012-08-07 2015-06-26 Novartis Ag
CA2879704A1 (en) * 2012-08-16 2014-02-20 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
US20160030440A1 (en) * 2013-04-05 2016-02-04 Sanofi Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525266A (ja) * 2003-05-02 2006-11-09 ノバルティス アクチエンゲゼルシャフト ホスファチジルイノシトール３−キナーゼの阻害剤
WO2009080694A1 (en) * 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
WO2010029082A1 (en) * 2008-09-10 2010-03-18 Novartis Ag Organic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
NZ587706A (en) * 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525266A (ja) * 2003-05-02 2006-11-09 ノバルティス アクチエンゲゼルシャフト ホスファチジルイノシトール３−キナーゼの阻害剤
WO2009080694A1 (en) * 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
WO2010029082A1 (en) * 2008-09-10 2010-03-18 Novartis Ag Organic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5014001058; ＣＡＲＭＥＬ　Ｔ．　ＣＨＡＮ: 'ＤＩＦＦＥＲＥＮＴＩＡＬ　ＳＥＮＳＩＴＩＶＩＴＩＥＳ　ＯＦ　ＴＲＡＳＴＵＺＵＭＡＢ　（ＨＥＲＣＥＰＴＩＮ（Ｒ））-ＲＥＳＩＳＴＡＮＴ　ＨＵＭＡＮ　ＢＲＥＡＳＴ　ＣＡＮＣＥＲ　以下備考' ＢＲＥＡＳＴ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ　ＡＮＤ　ＴＲＥＡＴＭＥＮＴ Ｖ９１　Ｎ２, 20050501, Ｐ１８７-２０１, ＫＬＵＷＥＲ　ＡＣＡＤＥＭＩＣ　ＰＵＢＬＩＳＨＥＲＳ *
JPN6015035499; Ｃａｎｃｅｒ　Ｃｅｌｌ，　２００５，　Ｖｏｌ．８，　ｐ．２８７-２９７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539149A (ja) * 2013-12-06 2016-12-15 ノバルティス アーゲー アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン

Also Published As

Publication number Publication date
BR112013009624A2 (pt) 2016-07-12
EP2637661A1 (en) 2013-09-18
CA2815492A1 (en) 2012-05-18
MX360157B (es) 2018-10-24
KR20130143582A (ko) 2013-12-31
CA2815492C (en) 2019-04-09
CN103200943A (zh) 2013-07-10
EP2637661B1 (en) 2017-12-20
WO2012062694A1 (en) 2012-05-18
AU2011328227A1 (en) 2013-04-18
KR101854484B1 (ko) 2018-05-03
MX2013005182A (es) 2013-07-03
JP2020114849A (ja) 2020-07-30
US20150250778A1 (en) 2015-09-10
RU2589695C2 (ru) 2016-07-10
US20130209461A1 (en) 2013-08-15
CN105412105A (zh) 2016-03-23
JP2016222686A (ja) 2016-12-28
TR201802943T4 (tr) 2018-03-21
RU2013126485A (ru) 2014-12-20
AU2011328227B2 (en) 2015-04-09
US20200022967A1 (en) 2020-01-23
JP2019048822A (ja) 2019-03-28
US20180325883A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
US20200022967A1 (en) Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
KR102112885B1 (ko) B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물
KR101950044B1 (ko) Ａｋｔ 억제제 화합물 및 베무라페닙의 조합물, 및 사용 방법
RU2496500C2 (ru) Применение производных пиримидина для лечения egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, направленным против членов семейства egfr
JP2023145689A (ja) Ｈｅｒ２陽性がんの処置
CN119746058A (zh) 治疗小细胞肺癌的联用药物组合物
CN105246508A (zh) Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
JP2013542228A5 (enExample)
CN113840601A (zh) 使用双特异性抗EGFR/c-Met抗体和第三代EGFR酪氨酸激酶抑制剂的组合疗法
CN113939315B (zh) 治疗黑色素瘤的联用药物组合物
US12472173B2 (en) Quinoline derivative and antibody soft tissue sarcoma combination therapy
AU2015203865B2 (en) Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
CN116802202A (zh) 癌症的联合治疗
CN116669763A (zh) Fgfr抑制剂联合疗法
CN114667159B (zh) 喹啉衍生物与pd-1单抗的药物组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160308